Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
NCT04410796
This study is recruiting at 15 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Non-small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Last updated on ClinicalTrials.gov
- September 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- UC Davis Cancer Center (Data Collection Only) · Sacramento, CA
Florida · 1
- Moffitt Cancer Center · Tampa, FL
Maryland · 1
- John Hopkins Medical Center · Baltimore, MD
Massachusetts · 1
- Massachusetts General Hospital (Data Collection Only) · Boston, MA
New Jersey · 4
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, NJ
- Hackensack Meridian Health · Hackensack, NJ
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, NJ
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, NJ
New York · 4
- Memorial Sloan Kettering Commack (Limited protocol activities) · Commack, NY
- Memorial Sloan Kettering Westchester (Limited protocol activities) · Harrison, NY
- Memorial Sloan Kettering Cancer Center (All protocol activities) · New York, NY
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) · Uniondale, NY
Tennessee · 1
- Sarah Cannon Research Institute · Nashville, TN
Texas · 1
- MD ANDERSON CANCER CENTER (Data Collection Only) · Houston, TX
Washington · 1
- University of Washington (Data Collection Only) · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.